New chemical entities and products

R&D

INN and/or CODE	Mechanism of action	Therapeutic indications	Development phase


Dexloxiglumide (CR 2017)	CCK-1 receptor antagonist	• Irritable Bowel Syndrome (IBS) • Functional dyspepsia (FD) • Gastro-Esophageal Reflux Disease (GERD)	Phase III (ongoing) Phase II (ongoing) Phase II (set-up)


Andolast (CR 2039)*	Airway specific anti-inflammatory agent with calcium-activated potassium channel opener properties	• Bronchial asthma • Allergic rhinitis • Chronic Obstructive Pulmonary Disease (COPD)	Phase III (set-up) Phase I (set-up) Phase II (on hold)


Itriglumide (CR 2945)*	CCK-2 receptor antagonist	• Anxiety disorders: - Generalized anxiety - Panic attacks • Acid-related gastrointestinal disorders: - Gastro-Esophageal Reflux Disease (GERD) - Peptic ulcer - Dyspepsia	Phase II (set-up) Phase II (on hold)


Neboglamine (CR 2249)†	Functional positive modulator of NMDA receptors with potent and selective inhibition of NE reuptake	• Schizophrenia (antipsychotic specifically effective on negative, cognitive and mood symptoms) • Drug abuse	Phase II (set-up) Phase I (set-up)


CR 3294	Inhibitor of pro-inflammatory gene expression with potent ROS-generation preventing effect	• Chemotherapy Induced Diarrhea (CID) • Chemotherapy/Radiotherapy-induced Mucositis • Inflammatory Bowel Diseases (IBD)	Phase I (set-up)


CR 3465‡	Leukotriene D4 receptor antagonist with a unique efficacy in urogenital inflammation models	• Bronchial asthma • Interstitial cystitis	Phase I (set-up)


CR 3394	NMDA receptor antagonist/IL-6 release inhibitor	Alzheimer's disease Parkinson disease	Pre-Clinical


4-oxo-fenretinide	Pro-apoptotic via ceramide induction	• Neuroblastoma (minimum residual disease therapy) • Breast cancer (chemoprevention) • Ovarian cancer (chemoprevention/therapy)	Pre-Clinical


CR 4056	Potent analgesic in different models of pain (Inflammatory, Neuropathic, Neurogenic) endowed with a novel undisclosed mode of action	• Neuropathic pain • Chronic Pain • Osteoarthritis • Fibromyalgia • Acute Nonspecific Pain	Pre-Clinical (pre-IND)


CR 3719 (series)	Cytokine Suppressive Anti-Inflammatory Drug (CSAID)	• Osteoarthritis (potent analgesic with combined distinct anti-inflammatory effect and Disease Modifying activity)	Pre-Clinical (lead optimization)


CR 4144/CR 4152 (series) CR 4153 (series) CR 4167 (series)	Aggrecanase Inhibitor	Osteoarthritis: Disease Modifying Drug	Pre-Clinical (hit-to-lead)


CR 3663	Undisclosed	Osteoarthritis: Disease Modifying Drug	Pre-Clinical (biological testing)


CR 2991‡	α_1A - adrenoceptor antagonist	Hypertension Prostatic hyperplasia	Pre-Clinical (on hold)


CR 3834‡	Angiotensin II AT1 receptor antagonist	Hypertension	Pre-Clinical (on hold)


CR 3124‡	5HT3 receptor antagonist	Chemotherapy-, Radiotherapy- Induced, Post-Operative Emesis Irritable Bowel Syndrome (IBS) Fibromyalgia Drug abuse	Pre-Clinical (on hold)


* Available for Outlicensing/Co-Development † Licensed ‡ Available for Outlicensing

INN and/or CODE	Mechanism of action	Therapeutic indications	Development phase